摘要:
Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is fluorine, or chlorine, and R2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.
摘要:
Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is fluorine, or chlorine, and R2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.
摘要:
The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
摘要:
The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
摘要翻译:本发明涉及式(I)的苯丙氨酸衍生物,其中X 1为卤素原子,X 2为卤素原子,Q为CH 2 R - 为可被酯化的羧基; 或其药学上可接受的盐。
摘要:
The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
摘要翻译:本发明涉及式(I)的苯丙氨酸衍生物,其中X 1为卤素原子,X 2为卤素原子,Q为CH 2 R - 为可被酯化的羧基; 或其药学上可接受的盐。
摘要:
The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
摘要翻译:本发明涉及式(I)的苯丙氨酸衍生物,其中X 1为卤素原子,X 2为卤素原子,Q为CH 2 R - 为可被酯化的羧基; 或其药学上可接受的盐。
摘要:
Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.
摘要:
The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
摘要:
A process for preparing S type 2-substituted hydroxy-2-indolidinyl-butyric ester compound [II]: ##STR1## wherein R.sup.0 is residue of nitrogen-containing fused heterocyclic carboxylic acid having absolute configuration of "R"(in which the nitrogen atom is protected), R.sup.1 and R.sup.2 are lower alkyl group, and E is ester residue, which is useful as an intermediate for preparing camptothecin derivatives having antitumor activities, which comprises 2-ethylating 2-substituted hydroxy-2-indolidinylacetic ester compound [I]: ##STR2## wherein the symbols are as defined above.
摘要翻译:一种制备S型2-取代羟基-2-吲哚哩啶基 - 丁酸酯化合物[II]的方法:其中R 0是具有绝对构型“R”(其中保护氮原子)的含氮稠合杂环羧酸的残基, R 1和R 2为低级烷基,E为酯残基,其可用作制备具有抗肿瘤活性的喜树碱衍生物的中间体,其包括2-乙基化2-取代的羟基-2-吲哚哩啶基乙酸酯化合物[I]:其中 符号如上所述。
摘要:
A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.